Johnson & Johnson halts rollout of vaccine in Europe amid US pause

Johnson & Johnson announced Tuesday it is delaying the rollout of its COVID-19 vaccine in Europe amid concerns about potential blood clots in US recipients.

“We are aware of an extremely rare disorder involving people with blood clots in combination with low platelets in a small number of individuals who have received our COVID-19 vaccine,” the New Jersey-based drugmaker said in a statement. “The United States Centers for Disease Control (CDC) and Food and Drug Administration (FDA) are reviewing data involving six reported U.S. cases out of more than 6.8 million doses administered,” J&J said.